Results 11 to 20 of about 2,600 (141)

medinfo quergelesen: Informationen aus dem Weblog medinfo / Skim through medinfo: Information from the medinfo weblog

GMS Medizin – Bibliothek – Information, 2007
Are you up to date? In July 2007 medinfo crossed the limit of 2000 news in the weblog. Many thanks to Oliver Obst for providing medical librarians with that much concentrated information.
Klein, Diana
doaj   +3 more sources

medinfo quergelesen: Informationen aus dem Weblog medinfo (September-Dezember 2007) / Skim through medinfo: Information from the medinfo weblog (September-December 2007)

GMS Medizin – Bibliothek – Information, 2007
Are you up to date? This article provides a selection of the most interesting contents of the weblog medinfo from September to December 2007.
Klein, Diana
doaj   +1 more source

Terveiset Medinfo 2015 konferenssista Sao Paolosta, Brasiliasta 19.–23.8.2015 [PDF]

Finnish Journal of eHealth and eWelfare, 2015
Medinfo konferenssin järjestää International Medical Informatics Association (IMIA). Konferenssi järjestetään kahden vuoden välein. Medinfo‐konferenssi on terveydenhuollon tietotekniikan ja tiedonhallinnan johtava tieteellinen maailmankonferenssi ...
Ulla-Mari Kinnunen
doaj   +1 more source

Predictive value of MRD monitoring by BCR clonality in the ZUMA-7 randomized clinical trial for CAR T therapy in r/r lymphoma. [PDF]

Br J Haematol
British Journal of Haematology, Volume 208, Issue 5, Page 1850-1853, May 2026.
Miles B, Mao D, Vardhanabhuti S, Bedognetti D, Filosto S, Shen R.   +5 more
europepmc   +2 more sources

Five-Year Outcomes With Delandistrogene Moxeparvovec in Patients With Duchenne Muscular Dystrophy: A Phase 1/2a Study. [PDF]

Muscle Nerve
ABSTRACT Aims We report 5‐year results from a phase 1/2a study of delandistrogene moxeparvovec, a recombinant adeno‐associated virus serotype rh74 vector‐based gene therapy for Duchenne muscular dystrophy (DMD), with post hoc analyses contextualizing functional outcomes. Methods Four ambulatory patients with DMD (≥ 4–< 8 years at enrollment) entered an
Mendell JR, Sahenk Z, Lowes LP, Iammarino MA, Alfano LN, McDonald CM, Signorovitch JE, Jin J, Li J, Mason S, Rodino-Klapac LR.   +10 more
europepmc   +2 more sources

Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial. [PDF]

Br J Haematol
British Journal of Haematology, Volume 208, Issue 2, Page 737-741, February 2026.
Komrokji RS, Santini V, Platzbecker U, Van Eygen K, Díez-Campelo M, de Paz R, Santillana GS, Thépot S, Kaźmierczak M, Oliva EN, Sekeres MA, Fenaux P, Madanat YF, Savona MR, Riggs J, Shah S, Lennox AL, Xia Q, Sun L, Berry T, Zeidan AM.   +20 more
europepmc   +2 more sources

Stakeholder Perspectives on the Use of Telehealth to Support Deprescribing for Older Patients Transitioning From the Hospital to Home Health Care. [PDF]

J Am Geriatr Soc
ABSTRACT Background Multimorbidity affects most older adults in home health care (HHC), leading to inappropriate polypharmacy and increased risks for adverse outcomes. While deprescribing can mitigate these risks, fragmented communication during hospital‐to‐home transitions remains a major barrier.
Wang J, Shen JY, Yu F, Simmons SF, Mixon AS, Nathan K, Moskow MS, Brasch JD, Norton SA, Heffner KL, Jiang Y, Seshadri S, Patel N, Song L, Zorek JA, Lam C, Caprio TV.   +16 more
europepmc   +2 more sources

Terlipressin for Hepatorenal Syndrome in Patients With Early-Stage Acute-on-Chronic Liver Failure. [PDF]

Liver Int
ABSTRACT Background & Aims Hepatorenal syndrome‐acute kidney injury (HRS‐AKI) is a life‐threatening complication of decompensated cirrhosis. The US Food and Drug Administration approved terlipressin use for HRS‐AKI based on the CONFIRM study, which demonstrated a significant improvement in HRS reversal with terlipressin versus placebo.
Rockey DC, Gordon F, Thuluvath PJ, Victor D, Kemmer N, Cardoza S, Jamil K, Frederick RT.   +7 more
europepmc   +2 more sources

Maralixibat Reduces Serum Bile Acids and Improves Cholestatic Pruritus in Adolescents With Alagille Syndrome. [PDF]

Liver Int
ABSTRACT Background Alagille syndrome (ALGS) is a multisystem cholestatic disorder. Maralixibat is approved for the treatment of cholestatic pruritus in ALGS with limited data in adults. Methods Participants were included if they received ≥ 2 doses of maralixibat at age ≥ 16 years in one of the three previously published maralixibat ALGS clinical ...
Hirschfield G, Vandriel SM, Mogul DB, Baek M, Vig P, Kamath BM.   +5 more
europepmc   +2 more sources

Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours. [PDF]

Clin Transl Med
Evidence suggests NOTCH activation is among the survival and proliferation pathways interacting with FOXL2 c.402C > G (p.Cys134Trp) mutation in granulosa cell tumours (GCT). This Phase II clinical trial of nirogacestat in GCT achieved its enrolment target in < 1 year and primary analysis within 2 years.
Grisham RN, Hopp E, Pennington K, Holloway R, Wenham RM, Blecharz P, Dockery L, Matsuo K, Salani R, Bidzinski M, Braly P, Celano P, Reid T, Seward S, Lewis J, Johnson M, DuBose R, Ahn S, Cheng S, Alvero C, Konstantinopoulos PA.   +20 more
europepmc   +2 more sources